Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. 2015

Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and often lethal malignant tumor. Several studies have shown that epithelial-mesenchymal transition (EMT) is frequently observed in clinical samples of PDA and is related to high metastatic rates and poor outcomes. To identify candidate molecules regulating EMT in PDA, we previously used cDNA microarray analysis and identified integrin β4 (ITGB4) as one of the genes upregulated in high-EMT xenografts derived from PDA patients. The aim of the current study was to clarify the clinicopathological and functional significance of ITGB4 overexpression in PDA. ITGB4 upregulation in high-EMT xenografts was confirmed by immunohistochemistry. Immunohistochemical analyses of 134 surgically resected PDA cases revealed intratumoral heterogeneity with respect to ITGB4 expression and showed that cancer cells undergoing EMT often display strong diffuse ITGB4 expression. High levels of ITGB4 expression were significantly correlated with the hallmarks of EMT (solitary cell infiltration, reduced E-cadherin expression, and increased vimentin expression), with high tumor grade, and with the presence of lymph node metastasis, and showed an independent prognostic effect. Immunocytochemical analyses of PDA cell lines revealed that localization of ITGB4 changed from regions of cell-cell contact to diffuse cytoplasm and cell edges with occasional localization in filopodia during EMT. Knockdown of ITGB4 reduced the migratory and invasive ability of PDA cells. Overexpression of ITGB4 promoted cell scattering and cell motility in combination with downregulation of E-cadherin and upregulation of vimentin expression. In conclusion, we elucidated the prognostic and clinicopathological significance of ITGB4 overexpression in PDA and also the potential role for ITGB4 in the regulation of cancer invasion and EMT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
July 2014, British journal of cancer,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
January 2009, Pancreas,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
January 2013, Molecular and clinical oncology,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
September 2016, Human pathology,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
March 2015, International journal of oncology,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
June 2013, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
January 2021, Frontiers in oncology,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
October 2021, Journal of gastrointestinal oncology,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
July 2021, World journal of clinical cases,
Y Masugi, and K Yamazaki, and K Emoto, and K Effendi, and H Tsujikawa, and M Kitago, and O Itano, and Y Kitagawa, and M Sakamoto
January 2019, Journal of Cancer,
Copied contents to your clipboard!